Radiotherapy combined with immunotherapy for non-small cell lung cancer (NSCLC), especially with PD-1/PD-L1 immune checkpoint inhibitors, have fallen under the spotlight in recent years. However, the combination therapy not only brings potential benefits to patients, but also alters the incidence of adverse events. At present, there is no adequate data to elucidate the incidence of adverse events in all-stage NSCLC patients. In this article, research progress on the toxicities of radiotherapy combined with immunotherapy for various stages of NSCLC, especially pneumonitis, was reviewed, aiming to maximize the benefits for patients with all-stage NSCLC.

Carcinoma, non-small-cell lung; Radiotherapy; Immunotherapy; Toxicity; Pneumonitis